{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:20:24Z","timestamp":1771827624424,"version":"3.50.1"},"reference-count":35,"publisher":"Jaypee Brothers Medical Publishing","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.59556\/japi.74.1374","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:53:02Z","timestamp":1771825982000},"page":"e1-e7","source":"Crossref","is-referenced-by-count":0,"title":["Role of \u03b2-Blockers Across the Cardiovascular Continuum: A Real-World Perception Survey (ROBUST)"],"prefix":"10.59556","volume":"74","author":[{"given":"JS","family":"Hiremath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arup","family":"Dasbiswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JPS","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhash","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PP","family":"Mohanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baishali","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20260223055259_B1","doi-asserted-by":"crossref","unstructured":"Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020;16(4):223\u2013237.","DOI":"10.1038\/s41581-019-0244-2"},{"issue":"(5):","key":"key20260223055259_B2","doi-asserted-by":"crossref","first-page":"e1002801.","DOI":"10.1371\/journal.pmed.1002801","article-title":"Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years.","volume":"16","author":"Prenissl","year":"2019;","journal-title":"PLoS Med"},{"key":"key20260223055259_B3","volume-title":"A race against time II: The challenge of cardiovascular diseases in developing economies.","author":"Huffman","year":"2014.","edition":"2nd edition."},{"key":"key20260223055259_B4","unstructured":"World Health Organization, South-East Asia Regional Office. (2026). About SEARO. [online] Available from: https:\/\/www.who.int\/southeastasia\/about. [Last accessed January, 2026]"},{"issue":"(1):","key":"key20260223055259_B5","doi-asserted-by":"crossref","first-page":"22\u2013","DOI":"10.2174\/1573402114666180918102735","article-title":"Three generations of \u03b2-blockers: history, class differences and clinical applicability.","volume":"15","author":"do Vale","year":"2019;","journal-title":"Curr Hypertens Rev"},{"issue":"(1):","key":"key20260223055259_B6","doi-asserted-by":"crossref","first-page":"5\u2013","DOI":"10.1111\/bcpt.12396","article-title":"Third-generation beta-adrenoceptor antagonists in the treatment of hypertension and heart failure.","volume":"117","author":"Fisker","year":"2015;","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"(10):","key":"key20260223055259_B7","doi-asserted-by":"crossref","first-page":"853\u2013","DOI":"10.1016\/j.recesp.2019.02.023","article-title":"Beta-blockers: Historical perspective and mechanisms of action.","volume":"72","author":"Oliver","year":"2019;","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"key20260223055259_B8","doi-asserted-by":"crossref","first-page":"779462.","DOI":"10.3389\/fcvm.2022.779462","article-title":"Long-term effect of \u03b2-blocker use on clinical outcomes in postmyocardial infarction patients: a systematic review and meta-analysis.","volume":"9:","author":"Liang","year":"2022;","journal-title":"Front Cardiovasc Med"},{"issue":"(9):","key":"key20260223055259_B9","doi-asserted-by":"crossref","first-page":"1635\u2013","DOI":"10.1080\/03007995.2018.1479245","article-title":"Metoprolol in the treatment of cardiovascular disease: a critical reappraisal.","volume":"34","author":"Grassi","year":"2018;","journal-title":"Curr Med Res Opin"},{"issue":"(1):","key":"key20260223055259_B10","doi-asserted-by":"crossref","first-page":"25\u2013","DOI":"10.2174\/1871525713666141219114708","article-title":"Beta-blockers and nitrates: pharmacotherapy and indications.","volume":"13","author":"Facchini","year":"2015;","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"key20260223055259_B11","doi-asserted-by":"crossref","first-page":"746988.","DOI":"10.3389\/fcvm.2021.746988","article-title":"Effects of metoprolol on periprocedural myocardial infarction after percutaneous coronary intervention (Type 4a MI): An inverse probability of treatment weighting analysis.","volume":"8:","author":"Li","year":"2021;","journal-title":"Front Cardiovasc Med"},{"issue":"(1):","key":"key20260223055259_B12","doi-asserted-by":"crossref","first-page":"6\u2013","DOI":"10.1016\/j.ihj.2023.12.009","article-title":"Comparison of Indian clinical practice guidelines for the management of hypertension with the World Health Organization, International Society of Hypertension, American, and European guidelines.","volume":"76","author":"Satheesh","year":"2024;","journal-title":"Indian Heart J"},{"issue":"(6):","key":"key20260223055259_B13","doi-asserted-by":"crossref","first-page":"1153\u2013","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","article-title":"Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: Indications beyond the 2018 European Society of Cardiology\/European Society of Hypertension Guidelines.","volume":"79","author":"Mancia","year":"2022;","journal-title":"Hypertension"},{"issue":"(5):","key":"key20260223055259_B14","doi-asserted-by":"crossref","first-page":"1021\u2013","DOI":"10.1161\/HYPERTENSIONAHA.124.22821","article-title":"Rationale for the inclusion of \u03b2-blockers among major antihypertensive drugs in the 2023 European Society of Hypertension Guidelines.","volume":"81","author":"Mancia","year":"2024;","journal-title":"Hypertension"},{"issue":"(10414):","key":"key20260223055259_B15","doi-asserted-by":"crossref","first-page":"1802\u2013","DOI":"10.1016\/S0140-6736(23)01733-6","article-title":"\u03b2-blockers switched to first-line therapy in hypertension.","volume":"402","author":"Messerli","year":"2023;","journal-title":"Lancet"},{"issue":"(10):","key":"key20260223055259_B16","doi-asserted-by":"crossref","first-page":"83\u2013","DOI":"10.59556\/japi.72.0715","article-title":"Position of beta-blockers in the treatment of hypertension today: an Indian consensus.","volume":"72","author":"Mohan","year":"2024;","journal-title":"J Assoc Physicians India"},{"issue":"(1):","key":"key20260223055259_B17","doi-asserted-by":"crossref","first-page":"15903.","DOI":"10.1038\/s41598-020-72836-4","article-title":"Treatment optimization of beta-blockers in chronic heart failure therapy.","volume":"10","author":"Niriayo","year":"2020;","journal-title":"Sci Rep."},{"issue":"(6):","key":"key20260223055259_B18","doi-asserted-by":"crossref","first-page":"475\u2013","DOI":"10.1093\/ehjcvp\/pvaa029","article-title":"Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction.","volume":"7","author":"Joo","year":"2021;","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"(14):","key":"key20260223055259_B19","doi-asserted-by":"crossref","first-page":"1495\u2013","DOI":"10.1161\/CIRCULATIONAHA.113.003653","article-title":"Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: The effect of metoprolol in cardioprotection during an acute myocardial infarction (METOCARD-CNIC) trial.","volume":"128","author":"Ibanez","year":"2013;","journal-title":"Circulation"},{"issue":"(22):","key":"key20260223055259_B20","doi-asserted-by":"crossref","first-page":"2356\u2013","DOI":"10.1016\/j.jacc.2014.03.014","article-title":"Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: Results from the METOCARD-CNIC trial (Effect of metoprolol in cardioprotection during an acute myocardial infarction).","volume":"63","author":"Pizarro","year":"2014;","journal-title":"J Am Coll Cardiol"},{"issue":"(18):","key":"key20260223055259_B21","doi-asserted-by":"crossref","first-page":"2093\u2013","DOI":"10.1016\/j.jacc.2016.02.050","article-title":"Impact of the timing of metoprolol administration during STEMI on infarct size and ventricular function.","volume":"67","author":"Garc\u00eda-Ruiz","year":"2016;","journal-title":"J Am Coll Cardiol"},{"issue":"(5):","key":"key20260223055259_B22","doi-asserted-by":"crossref","first-page":"55.","DOI":"10.1007\/s00395-020-0812-4","article-title":"Metoprolol blunts the time-dependent progression of infarct size.","volume":"115","author":"Lobo-Gonzalez","year":"2020;","journal-title":"Basic Res Cardiol"},{"issue":"(46):","key":"key20260223055259_B23","doi-asserted-by":"crossref","first-page":"4425\u2013","DOI":"10.1093\/eurheartj\/ehaa733","article-title":"Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation.","volume":"41","author":"Clemente-Morag\u00f3n","year":"2020;","journal-title":"Eur Heart J"},{"issue":"(23):","key":"key20260223055259_B24","doi-asserted-by":"crossref","first-page":"2705\u2013","DOI":"10.1016\/j.jacc.2016.03.522","article-title":"Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention.","volume":"67","author":"Roolvink","year":"2016;","journal-title":"J Am Coll Cardiol"},{"issue":"(1):","key":"key20260223055259_B25","doi-asserted-by":"crossref","first-page":"18\u2013","DOI":"10.4103\/jpcs.jpcs_59_23","article-title":"Hypertension management in pre- and post percutaneous coronary intervention patients: an expert opinion of cardiologists from India.","volume":"10","author":"Kumar","year":"2024;","journal-title":"J Pract Cardiovasc Sci"},{"issue":"(9):","key":"key20260223055259_B26","doi-asserted-by":"crossref","first-page":"956\u2013","DOI":"10.1016\/j.jacc.2023.06.006","article-title":"Chronic coronary disease guideline-at-a-glance.","volume":"82","author":"Winchester","year":"2023;","journal-title":"J Am Coll Cardiol"},{"issue":"(9):","key":"key20260223055259_B27","first-page":"e9\u2013","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"148","author":"Virani","year":"2023;","journal-title":"Circulation"},{"issue":"(1):","key":"key20260223055259_B28","first-page":"1\u2013","article-title":"Strategies for chronic coronary disease: A brief guide for clinicians.","volume":"1","author":"Krittanawong","year":"2024;","journal-title":"Cardiovasc Health"},{"issue":"(2):","key":"key20260223055259_B29","first-page":"e002597.","article-title":"\u03b2-blockers in atrial fibrillation patients with or without heart failure: Association with mortality in a nationwide cohort study.","volume":"9","author":"Nielsen","year":"2016;","journal-title":"Circ Heart Fail"},{"issue":"(9961):","key":"key20260223055259_B30","doi-asserted-by":"crossref","first-page":"2235\u2013","DOI":"10.1016\/S0140-6736(14)61373-8","article-title":"Efficacy of \u03b2 blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis.","volume":"384","author":"Kotecha","year":"2014;","journal-title":"Lancet"},{"issue":"(6):","key":"key20260223055259_B31","doi-asserted-by":"crossref","first-page":"831\u2013","DOI":"10.1007\/s00392-023-02295-0","article-title":"Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials.","volume":"113","author":"Perrett","year":"2024;","journal-title":"Clin Res Cardiol"},{"issue":"(5):","key":"key20260223055259_B32","doi-asserted-by":"crossref","first-page":"367\u2013","DOI":"10.18203\/2349-3933.ijam20231071","article-title":"Management of hypertensive patients with ischemic heart disease and the role of a fixed-dose combination of telmisartan and metoprolol: a physician-based research survey.","volume":"10","author":"Kathiresan","year":"2023;","journal-title":"Int J Adv Med"},{"key":"key20260223055259_B33","unstructured":"Food and Drug Administration. (2023). FDA Adverse Event Reporting System (FAERS) Public Dashboard. [online] Available from: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. [Last accessed January, 2026]"},{"issue":"(2):","key":"key20260223055259_B34","doi-asserted-by":"crossref","first-page":"445\u2013","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: A retrospective analysis using the FDA Adverse Events Reporting System.","volume":"40","author":"Silberstein","year":"2023;","journal-title":"Adv Ther."},{"key":"key20260223055259_B35","doi-asserted-by":"crossref","first-page":"107849.","DOI":"10.1016\/j.rmed.2024.107849","article-title":"\u03b2-blockers and asthma: Surprising findings from the FAERS database.","volume":"234:","author":"Cazzola","year":"2024;","journal-title":"Respir Med."}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:53:07Z","timestamp":1771825987000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-74-2-e1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.59556\/japi.74.1374"],"URL":"https:\/\/doi.org\/10.59556\/japi.74.1374","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}